Age-related Macular Degeneration (AMD)
Conditions
Keywords
Primary plan,, AMD characteristics,, brolucizumab
Brief summary
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.
Detailed description
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. PSS data was obtained from patients with wet AMD who enrolled in the program for the index period 10/10/2019 to 04/30/2020. * Identification period of the index period: 10/10/2019 to 04/30/2020 * Index date: Date of enrollment in the PSS program * Study Period: 10/10/2019 to 04/30/2020
Interventions
OTHERAll participants
All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients were enrolled in the brolucizumab PSS program * ≥19 years old
Exclusion criteria
• None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with Primary plan type | Index date defined as the date of enrollment in the PSS program | The primary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The primary Plan type include commercial, government or other insurance. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gender | Index date defined as the date of enrollment in the PSS program | Gender information of patients enrolled in the brolucizumab PSS program was reported |
| Patient region (by state) | Index date defined as the date of enrollment in the PSS program | Distribution of patients across US states |
| Provider region (by state) | Index date defined as the date of enrollment in the PSS program | Number of providers and their distribution across US states |
| Age | Index date defined as the date of enrollment in the PSS program | Age information of patients enrolled in the brolucizumab PSS program was reported |
| Number of patients with Secondary plan type | Index date defined as the date of enrollment in the PSS program | The secondary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The secondary plan included commercial, government or other insurance |
| Disease Status | Index date defined as the date of enrollment in the PSS program | The eye disease status of all the patients were reported. Disease status was categorized as Right eye, left eye, or bilateral |
| Insurance coverage | Index date defined as the date of enrollment in the PSS program | The insurance coverage details for all the patients with wet AMD was reported |
Countries
United States
Outcome results
None listed